Endorsement of Dual GIP/GLP-1 Therapies Marks New Era in Diabetes Treatment
PILLAR DIAGNOSTIC // WEEK 48
“All pillars unanimously support the favorable benefit–risk profile of dual GIP/GLP-1 and GLP-1 receptor agonists—demonstrating clinically meaningful weight loss, glycemic control, cardiovascular risk reduction, and good tolerability. No substantive conflicts emerged, indicating a low overall risk posture.”
Proposed action
Endorse broader clinical adoption of these agents in appropriate patient populations; implement standardized monitoring protocols for adverse events; support ongoing long-term safety studies and real-world data collection; and develop patient education materials to ensure informed use.
THE MECHANICS
Spread & delivery
—
THE MACHINE
Evidence & systems
Dual GIP/GLP-1 agonists like tirzepatide and GLP-1 receptor agonists such as semaglutide consistently drive clinically meaningful weight loss, glycemic improvements, cardiovascular risk reductions, and remain well tolerated across clinical trials and real‐world cohorts.
THE MAP
Policy & population
—
THE MOOD
Trust & behavior
People feel hopeful that medications may provide effective treatment.